CAConstance T. Albarracin

Constance T. Albarracin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Constance T. Albarracin has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figure S2 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    Supplementary Figure S2 shows Kaplan-Meier cumulative incidence of invasive cancer curves, with patients categorized according to whether they had undergone excision at 6 months or not.

  • Open Access

    Supplementary Figure S3 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    Supplementary Figure S3 shows the cumulative incidence of invasive cancer or DCIS curves under each treatment strategy.

  • Open Access

    Supplementary Table S1 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    Supplementary Table S1 shows the baseline characteristics for all individuals eligible for the study.

  • Open Access

    Supplementary Table S2 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    Supplementary Table S2 shows the cumulative incidence of invasive cancer or DCIS by year under each treatment strategy.

  • Open Access

    Supplementary Table S4 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    Supplementary Table S4 shows points estimates for the cumulative incidence of invasive cancer at 5 years under each treatment strategy in a sensitivity analysis that used parametric standardization rather than inverse probability weighting.

  • Open Access

    Supplementary Table S3 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    Supplementary Table S3 shows point estimates for the cumulative incidence of invasive cancer at 5 years under each treatment strategy in a sensitivity analysis that varied the inverse probability weight truncation threshold.

  • Open Access

    Data from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    The recently published 2-year outcomes of the comparing an operation to monitoring, with or without endocrine therapy (COMET) trial provide evidence for the noninferiority of active monitoring of ductal carcinoma in situ (DCIS), compared with excision. These findings raise questions for the management of atypical ductal hyperplasia (ADH). To assess whether active monitoring is a safe strategy in selected patients with ADH, we used observational data on women diagnosed at an academic comprehensive cancer center and emulated a target trial of surgical excision versus active monitoring. Eligibility criteria were adapted from the COMET trial: age 40 years or older, without concurrent malignancy or a history of ipsilateral breast cancer or DCIS within the prior 5 years, without breast cancer symptoms, with no mass on physical examination or imaging, and without a history of recent endocrine therapy use. We estimated the risk of ipsilateral invasive carcinoma. There were 673 women with low-risk ADH, 238 (35.4%) of whom underwent surgical excision within 6 months. The risk of ipsilateral invasive carcinoma was 2.4% [95% confidence interval (CI), 0.8–4.1%] at 2 years with surgical excision and 0.4% (95% CI, 0–0.9%) with active monitoring (difference: 2.0; 95% CI, 0.3–3.8). At 5 years, the risk was 2.4% (95% CI, 0.8–4.2%) with surgical excision and 1.8% (0.7–3.3%) with active monitoring (difference: 0.5; 95% CI, −1.6 to 2.6). All cancers diagnosed at surgical excision or during follow-up were stage I. These findings provide evidence that active monitoring is safe and does not increase the risk of invasive carcinoma compared with surgical excision in patients with low-risk ADH. Prevention Relevance:Surgical excision is commonly performed for ADH of the breast. This study found that women with low-risk ADH had a very low risk of invasive cancer with active monitoring, which was similar to the risk under surgical excision. The findings support omission of surgery in these patients.See related Spotlight, p. 555

  • Open Access

    Supplementary Figure S1 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    Supplementary Figure S1 is a flow diagram depicting the application of eligibility criteria used to derive the final analytic cohort.

  • Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    The recently published 2-year outcomes of the comparing an operation to monitoring, with or without endocrine therapy (COMET) trial provide evidence for the noninferiority of active monitoring of ductal carcinoma in situ (DCIS), compared with excision. These findings raise questions for the management of atypical ductal hyperplasia (ADH). To assess whether active monitoring is a safe strategy in selected patients with ADH, we used observational data on women diagnosed at an academic comprehensive cancer center and emulated a target trial of surgical excision versus active monitoring. Eligibility criteria were adapted from the COMET trial: age 40 years or older, without concurrent malignancy or a history of ipsilateral breast cancer or DCIS within the prior 5 years, without breast cancer symptoms, with no mass on physical examination or imaging, and without a history of recent endocrine therapy use. We estimated the risk of ipsilateral invasive carcinoma. There were 673 women with low-risk ADH, 238 (35.4%) of whom underwent surgical excision within 6 months. The risk of ipsilateral invasive carcinoma was 2.4% [95% confidence interval (CI), 0.8–4.1%] at 2 years with surgical excision and 0.4% (95% CI, 0–0.9%) with active monitoring (difference: 2.0; 95% CI, 0.3–3.8). At 5 years, the risk was 2.4% (95% CI, 0.8–4.2%) with surgical excision and 1.8% (0.7–3.3%) with active monitoring (difference: 0.5; 95% CI, −1.6 to 2.6). All cancers diagnosed at surgical excision or during follow-up were stage I. These findings provide evidence that active monitoring is safe and does not increase the risk of invasive carcinoma compared with surgical excision in patients with low-risk ADH. Prevention Relevance: Surgical excision is commonly performed for ADH of the breast. This study found that women with low-risk ADH had a very low risk of invasive cancer with active monitoring, which was similar to the risk under surgical excision. The findings support omission of surgery in these patients.


  • TRPS1 expression in neuroendocrine neoplasms of breast and other organs

    by Qiqi Ye, Jeannelyn Estrella, Neda Kalhor, Audrey Liu, Cody Han, Hongxia Sun, Lavinia P Middleton, Hui Chen, Constance Albarracin, Aysegul Sahin, et al.

    Background: Primary neuroendocrine (NE) neoplasms of the breast are rare. In the absence of in situ carcinoma, metastasis from other organs needs to be ruled out first. TRPS1 is a recently identified marker for breast origin. In the current study, we investigated TRPS1 expression in breast neuroendocrine neoplasms, including well‐differentiated neuroendocrine tumour (NET) and poorly differentiated neuroendocrine carcinoma (NEC), and compared its expression with neuroendocrine neoplasms from other organs, such as lung, gastrointestinal tract and pancreas. Methods and results: A total of 105 cases of NE neoplasms were included in our study cohort, including 56 from breast (39 NETs and 17 NECs), 18 from lung (12 typical and atypical carcinoids, and 6 NECs), 19 from gastrointestinal tract (10 NETs, 3 NECs, 6 NETs metastases to breast) and 12 from pancreas (9 NETs, 3 NECs). TRPS1 exhibited moderate to strong expression in 38 of 39 breast NETs (97.4%). Four of 17 (23.5%) breast NECs showed weak to moderate staining. By contrast, no TRPS1 staining was observed in any of the 18 lung and 12 pancreatic NE neoplasms. Among 19 gastrointestinal NE neoplasms, only 1 NEC displayed scattered low TRPS1 positivity. Conclusions: Our study demonstrated that TRPS1 is universally expressed in mammary NET, and it is a valuable marker to distinguish primary mammary NET from metastatic NET of other organs, including lung, gastrointestinal tract and pancreas. TRPS1 has limited utility in differentiating mammary NEC from NEC of other organs. Clinical radiographic correlation is paramount in diagnosing primary NEC of the breast.